For the quarter ending 2026-03-31, CGEM has $402,984K in assets. $36,812K in debts. $75,081K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 75,081 | 88,332 | 103,335 | 72,820 |
| Short-term investments | 276,804 | 289,564 | 229,261 | 192,662 |
| Prepaid expenses and other current assets | 9,522 | 8,860 | 9,639 | 10,429 |
| Total current assets | 361,407 | 386,756 | 342,235 | 275,911 |
| Total property and equipment, gross | - | 1,390 | - | - |
| Less accumulated depreciation | - | 969 | - | - |
| Property and equipment, net | 342 | 421 | 489 | 569 |
| Operating lease right-of-use assets | 2,437 | 2,630 | 1,046 | 1,180 |
| Other assets | 297 | 297 | 361 | 367 |
| Long-term investments | 38,501 | 58,270 | 139,995 | 242,302 |
| Total assets | 402,984 | 448,374 | 484,126 | 520,329 |
| Accounts payable | 2,509 | 841 | 1,722 | 2,461 |
| Accrued expenses and other current liabilities | 31,920 | 36,120 | 29,847 | 24,203 |
| Operating lease liabilities, current | 725 | 780 | 1,188 | 1,394 |
| Total current liabilities | 35,154 | 37,741 | 32,757 | 28,058 |
| Operating lease liabilities, net of current portion | 1,658 | 1,903 | 0 | 125 |
| Total liabilities | 36,812 | 39,644 | 32,757 | 28,183 |
| Common stock, 0.0001 par value, 150,000,000 shares authorized as of december 31, 2025 and 2024 60,244,136 and 58,510,610 shares issued and outstanding as of december 31, 2025 and 2024, respectively | - | 6 | 6 | 6 |
| Additional paid-in capital | - | 995,823 | 987,796 | 978,329 |
| Accumulated other comprehensive gain (loss) | - | 1,020 | 973 | 607 |
| Accumulated deficit | - | -588,119 | -537,406 | -486,796 |
| Total cullinan stockholders' equity | - | 408,730 | 451,369 | 492,146 |
| Noncontrolling interests | - | 0 | 0 | 0 |
| Total stockholders' equity | 366,172 | 408,730 | 451,369 | 492,146 |
| Total liabilities and stockholders' equity | 402,984 | 448,374 | 484,126 | 520,329 |
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)